Cabozantinib
Other Protein Kinase Inhibitors
Sold as Cometriq · Cabometyx
- Drug class
- Other Protein Kinase Inhibitors
- Availability
- See label
- Routes
- Oral
- Markets covered
- 3
- Products on record
- 26
Overview
Cabozantinib is an active pharmaceutical ingredient in the Other Protein Kinase Inhibitors group (L01EX). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 21 | May 15, 2026 |
| EU European Union | EMA | 2 | February 27, 2026 |
| CA Canada | Health Canada | 3 | December 31, 2025 |
GBUnited Kingdom· MHRA
21 products
Uses
1). 1). Hepatocellular carcinoma (HCC) Cabozantinib Ipsen is indicated as monotherapy for the treatment of hepatocellular carcinoma (HCC) in adults who have previously been treated with sorafenib. Differentiated thyroid carcinoma (DTC) Cabozantinib Ipsen is indicated as monotherapy for the treatment of adult patients with locally advanced or metastatic differentiated thyroid carcinoma (DTC), refractory or not eligible to radioactive iodine (RAI) who have progressed during or after prior systemic therapy.
Neuroendocrine Tumours (NET) Cabozantinib Ipsen is indicated for the treatment of adult patients with unresectable or metastatic, well differentiated extra-pancreatic (epNET) and pancreatic (pNET) neuroendocrine tumours who have progressed following at least one prior systemic therapy other than somatostatin analogues.
EUEuropean Union· EMA
2 products
Uses
COMETRIQ is indicated for the treatment of adult patients with progressive, unresectable locally advanced or metastatic medullary thyroid carcinoma. 1).
How to take
CACanada· Health Canada
3 products
3 products on record with this regulator. Detailed label text (uses, dosage, side effects) is being ingested — the original document is linked under Sources [3].
Brands in Canada (1)
Drug interactions
Known interactions involving Cabozantinib. Select one for details. This list is informational and not a complete interaction checker.
Showing 240 of 437. Type above to find a specific drug.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PLGB282470003 · revised May 15, 2026
- [2]European Medicines Agency · EMEA/H/C/002640 · revised February 27, 2026
- [3]Health Canada (DPD) · 02480824 · revised December 31, 2025
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.